Inhalable tRNA Therapy Reverses CF Defect, Paving Way for Other Genetic Diseases
TL;DR Summary
University of Toronto researchers engineered an inhalable, modified tRNA that can read through premature stop codons in CFTR mRNA, restoring CFTR protein in mice and persisting in lung tissue for up to 40 days; in patient-derived organoids, tRNA plus the CF drug Trikafta restored function where the drug alone failed. The study suggests tRNA therapies may complement mRNA approaches and could be extended to Duchenne muscular dystrophy and Rett syndrome, with plans to move toward clinical trials in 2–3 years.
- With mRNA back in the spotlight, tRNA shows potential to treat genetic disease Fierce Biotech
- Next-generation RNA approach provides hope for genetic diseases missed by current drugs Medical Xpress
- Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models Genetic Engineering and Biotechnology News
- Could Transfer RNA Therapies Best mRNA for Cystic Fibrosis? Precision Medicine Online
- Scientists in Canada find RNA therapy approach that acts like biological bypass Hindustan Times
Reading Insights
Total Reads
1
Unique Readers
9
Time Saved
3 min
vs 4 min read
Condensed
88%
671 → 80 words
Want the full story? Read the original article
Read on Fierce Biotech